{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:10:59Z","timestamp":1781629859604,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","award":["Pfizer Inc"],"award-info":[{"award-number":["Pfizer Inc"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Canc Educ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with multiple myeloma (MM), patient advocates, healthcare providers (HCPs), and industry sponsors gathered at 2 MM Health Equity Summits to discuss their experiences and perspectives on MM healthcare inequities in the US. Eight topics relevant to the patient experience were identified at the first summit, prioritized by participant survey, and aligned on by the entire group. Two topics were then selected for priority discussion in the follow-up summit, which led to the insights presented here and actionable steps for US HCPs, policy makers, and other stakeholders. The first topic centered around delivering precise information specific to a patient\u2019s disease journey, emphasizing awareness and understanding. Lack of MM awareness and its symptoms among non-specialist HCPs and patients was identified as the primary cause for delayed diagnoses in patients with generalized symptoms. Participants suggested that enhancing HCP MM trainings and resources may aid timely diagnoses. Furthermore, using diverse communication channels and leveraging support groups and community health workers may improve MM education for patients, caregivers, and other family members and promote self-advocacy. The second topic focused on improving access to optimal care. Participants discussed how geographical, cultural, and financial factors influence access to specialized treatment. Proposed solutions included telehealth, reducing potential HCP biases in referrals, and using patient navigators to aid with insurance obstacles. Participants also discussed ways to improve perceptions of clinical trials. The MM Health Equity Summits allowed patients and patient advocates to discuss experiences and treatment access barriers. Actionable steps were recommended for HCPs and policymakers to improve treatment of disadvantaged patients, redressing historic inequities, and focusing on solutions to expand awareness, understanding, and access to healthcare.<\/jats:p>","DOI":"10.1007\/s13187-025-02798-6","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T04:29:44Z","timestamp":1768537784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actionable Steps to Address Disparities in Healthcare Among US Patients With Multiple Myeloma: A Patient Perspective"],"prefix":"10.1007","author":[{"given":"Oya","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Omel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G.","family":"Ortiz-Ravick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily D.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpitha","family":"Soussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-3768","authenticated-orcid":false,"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"1","key":"2798_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2798_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107","journal-title":"Am J Hematol"},{"issue":"17","key":"2798_CR3","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1182\/bloodadvances.2022007127","volume":"13","author":"EK O\u2019Donnell","year":"2022","unstructured":"O\u2019Donnell EK, Shapiro YN, Yee AJ et al (2022) Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv 13(17):4967\u20134974","journal-title":"Blood Adv"},{"issue":"1","key":"2798_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2217\/pmt-2021-0013","volume":"12","author":"B Quinn","year":"2022","unstructured":"Quinn B, Ludwig H, Bailey A et al (2022) Physical, emotional and social pain communication by patients diagnosed and living with multiple myeloma. Pain Manag 12(1):59\u201374","journal-title":"Pain Manag"},{"issue":"3","key":"2798_CR5","doi-asserted-by":"publisher","DOI":"10.2196\/39068","volume":"8","author":"M Lyall","year":"2022","unstructured":"Lyall M, Crawford R, Bell T et al (2022) Characterizing the patient journey in multiple myeloma: qualitative review. JMIR Cancer 8(3):e39068","journal-title":"JMIR Cancer"},{"issue":"Supplement 1","key":"2798_CR6","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1182\/blood-2021-146910","volume":"138","author":"LD Notardonato","year":"2021","unstructured":"Notardonato LD, Langerman SS, Zhou J, Calip GS, Chiu BC-H, Derman BA (2021) Racial disparities in the diagnostic evaluation of multiple myeloma. Blood 138(Supplement 1):4116\u20134117","journal-title":"Blood"},{"key":"2798_CR7","unstructured":"SEER*Explorer(2024) An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute, Updated 17 April 2024, Data source(s): SEER Incidence Data, November 2023 Submission (1975\u20132021), SEER 22 registries. Accessed 11 June 2024. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"2798_CR8","unstructured":"SEER(2024) Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. Accessed 19 April 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"issue":"10","key":"2798_CR9","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1038\/bcj.2017.97","volume":"7","author":"O Landgren","year":"2017","unstructured":"Landgren O, Graubard BI, Kumar S et al (2017) Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10\u201349 years old: a population-based study from the National health and nutrition examination survey. Blood Cancer J 7(10):e618\u2013e618","journal-title":"Blood Cancer J"},{"issue":"24","key":"2798_CR10","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.2019000406","volume":"133","author":"NR Fillmore","year":"2019","unstructured":"Fillmore NR, Yellapragada SV, Ifeorah C et al (2019) With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood 133(24):2615\u20132618","journal-title":"Blood"},{"issue":"7","key":"2798_CR11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1055-9965.EPI-17-0092","volume":"26","author":"KD Blake","year":"2017","unstructured":"Blake KD, Moss JL, Gaysynsky A, Srinivasan S, Croyle RT (2017) Making the case for investment in rural cancer control: an analysis of rural cancer incidence, mortality, and funding trends. Cancer Epidemiol Biomarkers Prev 26(7):992\u2013997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"20","key":"2798_CR12","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1002\/cncr.30183","volume":"122","author":"LJ Costa","year":"2016","unstructured":"Costa LJ, Brill IK, Brown EE (2016) Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer 122(20):3183\u20133190","journal-title":"Cancer"},{"issue":"1","key":"2798_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1370\/afm.2632","volume":"19","author":"M Bazargan","year":"2021","unstructured":"Bazargan M, Cobb S, Assari S (2021) Discrimination and medical mistrust in a racially and ethnically diverse sample of California adults. Ann Fam Med 19(1):4\u201315","journal-title":"Ann Fam Med"},{"key":"2798_CR14","doi-asserted-by":"crossref","unstructured":"Bhutani M, Blue BJ, Cole C et al (2023) Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer J 13(1):189","DOI":"10.1038\/s41408-023-00961-0"},{"issue":"4","key":"2798_CR15","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1200\/JOP.19.00309","volume":"16","author":"V Kumar","year":"2020","unstructured":"Kumar V, Alhaj-Moustafa M, Bojanini L et al (2020) Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care. JCO Oncol Pract 16(4):e341\u2013e349","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"2798_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","volume":"7","author":"BA Derman","year":"2020","unstructured":"Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC (2020) Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J 7(8):80","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"2798_CR17","first-page":"4352","volume":"130","author":"V Bhatnagar","year":"2017","unstructured":"Bhatnagar V, Gormley N, Kazandjian D et al (2017) FDA analysis of racial demographics in multiple myeloma trials. Blood 130:4352\u20134352","journal-title":"Blood"},{"issue":"32","key":"2798_CR18","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1200\/JCO.22.00504","volume":"40","author":"M Casey","year":"2022","unstructured":"Casey M, Odhiambo L, Aggarwal N et al (2022) Are pivotal clinical trials for drugs approved for leukemias and multiple myeloma representative of the population at risk? J Clin Oncol 40(32):3719\u20133729","journal-title":"J Clin Oncol"},{"issue":"2","key":"2798_CR19","first-page":"147","volume":"115","author":"LD Knox","year":"2023","unstructured":"Knox LD, Seide CW (2023) Black men in white coats - Barriers black men face in medicine, implications to decreased representation, and potential interventions at the uniformed services university of the health sciences. J Natl Med Assoc 115(2):147\u2013156","journal-title":"J Natl Med Assoc"},{"issue":"9","key":"2798_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.clml.2023.05.005","volume":"23","author":"B Blue","year":"2023","unstructured":"Blue B, Pierre A, Mikhael J (2023) Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma. Clin Lymphoma Myeloma Leuk 23(9):651\u2013659","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2798_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00277-012-1641-9","volume":"92","author":"N Hjortholm","year":"2013","unstructured":"Hjortholm N, Jaddini E, Ha\u0142aburda K et al (2013) Strategies of pain reduction during the bone marrow biopsy. Ann Hematol 92(2):145\u2013149","journal-title":"Ann Hematol"},{"key":"2798_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2257.2004.00608.x","volume":"26","author":"I Giannoutsos","year":"2024","unstructured":"Giannoutsos I, Grech H, Maboreke T et al (2024) Performing bone marrow biopsies with or without sedation: a comparison. Clin Lab Haematol 26:201\u2013204","journal-title":"Clin Lab Haematol"},{"issue":"17","key":"2798_CR23","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2217\/fon-2022-1267","volume":"19","author":"J Clements","year":"2023","unstructured":"Clements J, Fleischman A, Lerner V, Ruiz C (2023) The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist. Future Oncol 19(17):1197\u20131208","journal-title":"Future Oncol"},{"key":"2798_CR24","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951525000471","volume":"23","author":"OO Ansah","year":"2025","unstructured":"Ansah OO, Daniels-Donkor SS, Ledbetter L et al (2025) Exploring the landscape of palliative care provision for black patients with hematologic cancers: a scoping review. Palliat Support Care 23:e96","journal-title":"Palliat Support Care"},{"issue":"3","key":"2798_CR25","doi-asserted-by":"publisher","first-page":"pkae032","DOI":"10.1093\/jncics\/pkae032","volume":"8","author":"E Haines","year":"2024","unstructured":"Haines E, Shelton RC, Foley K et al (2024) Addressing social needs in oncology care: another research-to-practice gap. JNCI Cancer Spectr 8(3):pkae032","journal-title":"JNCI Cancer Spectr"},{"issue":"5","key":"2798_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40615-019-00602-y","volume":"6","author":"A Ma","year":"2019","unstructured":"Ma A, Sanchez A, Ma M (2019) The impact of patient-provider race\/ethnicity concordance on provider visits: updated evidence from the medical expenditure panel survey. J Racial Ethn Health Disparities 6(5):1011\u20131020","journal-title":"J Racial Ethn Health Disparities"}],"container-title":["Journal of Cancer Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-025-02798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13187-025-02798-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-025-02798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:47:03Z","timestamp":1781628423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13187-025-02798-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":26,"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1007\/s13187-025-02798-6","relation":{},"ISSN":["0885-8195","1543-0154"],"issn-type":[{"value":"0885-8195","type":"print"},{"value":"1543-0154","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work did not involve research on humans. The manuscript summarizes the findings from two meetings (MM Health Equity Summits) attended by experts on the topic from various perspectives, including treating physicians, patient advocacy groups, as well as patients living with the disease. The participants discussed the topic reported in this work during the meetings, which were not related to any clinical trial and no intervention was used. Pfizer helped organize the meeting; however, none of the patients who participated in the meetings had enrolled in any Pfizer-sponsored clinical trial. Furthermore, since there was no collection of patient data and the individual experiences were not identifiable, ethical approval was not required per federal regulations 45 CFR 46.104(d).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants consented to participate in the summits.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"OG\n                      ,\n                      JO\n                      ,\n                      PP\n                      ,\n                      AD\n                      ,\n                      LO-R\n                      , and\n                      EG\n                      report no conflicts of interest;\n                      RS\n                      and\n                      ES\n                      report employment at and stock ownership with Pfizer;\n                      BB\n                      reports consultancy role for AbbVie, Janssen, Kite Pharmaceuticals, Oncopeptides, Pfizer, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}